Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 3 (March)

1. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth.
   FASEB J, 21(3): 754-65. [Abstract] [Full-text]
2. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
   Cancer Res, 67(5): 2290-7. [Abstract] [Full-text]
3. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
   Cancer Res, 67(5): 2247-55. [Abstract] [Full-text]
4. Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors.
   Cancer Res, 67(5): 2197-205. [Abstract] [Full-text]
5. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo.
   Cancer Res, 67(5): 2141-9. [Abstract] [Full-text]
6. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
   Cancer Immunol Immunother, 56(5): 725-30. [Abstract] [Full-text]
7. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
   Cancer Immunol Immunother, 56(5): 689-98. [Abstract] [Full-text]
8. Screening for prostate cancer: a Cochrane systematic review.
   Cancer Causes Control, 18(3): 279-85. [Abstract] [Full-text]
9. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
   J Cell Physiol, 211(2): 533-43. [Abstract] [Full-text]
10. The current role of imaging for prostate brachytherapy.
    Cancer Imaging, 7: 27-33. [Abstract] [Full-text]
11. A case-control study of farming and prostate cancer in African-American and Caucasian men.
    Occup Environ Med, 64(3): 155-60. [Abstract] [Full-text]
12. Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
    Expert Rev Anticancer Ther, 7(3): 383-90. [Abstract] [Full-text]
13. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status.
    Cancer Lett, 248(2): 251-61. [Abstract] [Full-text]
14. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
    J Natl Cancer Inst, 99(5): 376-85. [Abstract] [Full-text]
15. Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation.
    Oncogene, 26(11): 1606-15. [Abstract] [Full-text]
16. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells.
    Int J Cancer, 120(9): 2034-43. [Abstract] [Full-text]
17. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.
    Int J Cancer, 120(9): 2028-33. [Abstract] [Full-text]
18. Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy.
    J Clin Oncol, 25(8): 987-95. [Abstract] [Full-text]
19. Haploinsufficiency of 8p22 may influence cancer-specific survival in prostate cancer.
    Cancer Genet Cytogenet, 174(1): 24-34. [Abstract] [Full-text]
20. Non-invasive imaging of firefly luciferase reporter gene expression using bioluminescence imaging in human prostate cancer models.
    Biotechnol Appl Biochem, 46: 179-84. [Abstract] [Full-text]
21. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy.
    Int J Cancer, 120(8): 1603-9. [Abstract] [Full-text]
22. A recurrent mutation in PALB2 in Finnish cancer families.
    Nature, 446(7133): 316-9. [Abstract] [Full-text]
23. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.
    Mol Cancer, 6: 18. [Abstract] [Full-text]
24. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia.
    Cancer Causes Control, 18(4): 375-84. [Abstract] [Full-text]
25. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    J Clin Oncol, 25(9): 1038-42. [Abstract] [Full-text]
26. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas.
    Hum Pathol, 38(4): 564-9. [Abstract] [Full-text]
27. Prostate stem cells: from development to cancer.
    Semin Cancer Biol, 17(3): 219-24. [Abstract] [Full-text]
28. Differential expression of CD10 in prostate cancer and its clinical implication.
    BMC Urol, 7: 3. [Abstract] [Full-text]
29. An integrated Monte Carlo dosimetric verification system for radiotherapy treatment planning.
    Phys Med Biol, 52(7): 1991-2008. [Abstract] [Full-text]
30. A method to calculate coverage probability from uncertainties in radiotherapy via a statistical shape model.
    Phys Med Biol, 52(7): 1947-65. [Abstract] [Full-text]
31. E2F4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma.
    Oncogene, 26(13): 1897-909. [Abstract] [Full-text]
32. Tumor suppressor activity of glucocorticoid receptor in the prostate.
    Oncogene, 26(13): 1885-96. [Abstract] [Full-text]
33. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression.
    Oncogene, 26(13): 1875-84. [Abstract] [Full-text]
34. Molecular markers for prostate cancer.
    Cancer Lett, 249(1): 5-13. [Abstract] [Full-text]
35. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
    Cancer Lett, 249(1): 18-29. [Abstract] [Full-text]
36. Prostate-specific antigen in clinical practice.
    Cancer Lett, 249(1): 30-9. [Abstract] [Full-text]
37. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies.
    J Urol, 177(4): 1324-9; quiz 1591. [Abstract] [Full-text]
38. Detection of sentinel node micrometastasis by step section and immunohistochemistry in patients with prostate cancer.
    J Urol, 177(4): 1313-7; discussion 1317. [Abstract] [Full-text]
39. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
    J Urol, 177(4): 1307-12. [Abstract] [Full-text]
40. Prostate cancer screening and disease management: how screening may have an unintended effect on survival and mortality-the camel's nose effect.
    J Urol, 177(4): 1303-6. [Abstract] [Full-text]
41. The association between total prostate specific antigen concentration and prostate specific antigen velocity.
    J Urol, 177(4): 1298-302; discussion 1301-2. [Abstract] [Full-text]
42. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
    J Urol, 177(4): 1229-37. [Abstract] [Full-text]
43. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.
    Qual Life Res, 16(4): 571-5. [Abstract] [Full-text]
44. NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells.
    Cell Signal, 19(5): 1093-100. [Abstract] [Full-text]
45. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
    Eur Urol, 51(5): 1175-84. [Abstract] [Full-text]
46. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
    Eur Urol, 51(5): 1252-8. [Abstract] [Full-text]
47. Laparoscopic radical prostatectomy in men older than 70 years of age with localized prostate cancer: comparison of morbidity, reconvalescence, and short-term clinical outcomes between younger and older men.
    Eur Urol, 51(5): 1341-8; discussion 1349. [Abstract] [Full-text]
48. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome.
    Eur Urol, 51(5): 1244-50; discussion 1251. [Abstract] [Full-text]
49. Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy.
    Eur Urol, 51(5): 1229-35. [Abstract] [Full-text]
50. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network.
    Eur Urol, 51(5): 1236-40; discussion 1241-3. [Abstract] [Full-text]
51. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Eur Urol, 51(5): 1259-66. [Abstract] [Full-text]
52. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues.
    Prostate, 67(6): 638-44. [Abstract] [Full-text]
53. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
    Prostate, 67(6): 630-7. [Abstract] [Full-text]
54. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Prostate, 67(6): 653-60. [Abstract] [Full-text]
55. Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy.
    Prostate, 67(6): 645-52. [Abstract] [Full-text]
56. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP).
    Prostate, 67(6): 661-73. [Abstract] [Full-text]
57. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha.
    Prostate, 67(6): 623-9. [Abstract] [Full-text]
58. Genome-wide linkage analysis for aggressive prostate cancer in Utah high-risk pedigrees.
    Prostate, 67(6): 605-13. [Abstract] [Full-text]
59. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
    Prostate, 67(6): 614-22. [Abstract] [Full-text]
60. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
    Prostate, 67(6): 603-4. [Abstract] [Full-text]
61. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention.
    Prostate, 67(6): 582-90. [Abstract] [Full-text]
62. The oncogenic potential of a prostate cancer-derived androgen receptor mutant.
    Prostate, 67(6): 591-602. [Abstract] [Full-text]
63. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
    Cancer, 109(7): 1279-89. [Abstract] [Full-text]
64. Radical prostatectomy for clinical stage T3a disease.
    Cancer, 109(7): 1273-8. [Abstract] [Full-text]
65. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    Cancer, 109(7): 1290-5. [Abstract] [Full-text]
66. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Nat Clin Pract Oncol, 4(4): 236-44. [Abstract] [Full-text]
67. Imaging prostate cancer: a multidisciplinary perspective.
    Radiology, 243(1): 28-53. [Abstract] [Full-text]
68. Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer.
    J Cancer Res Clin Oncol, 133(5): 297-304. [Abstract] [Full-text]
69. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
    Cancer Immunol Immunother, 56(6): 885-95. [Abstract] [Full-text]
70. Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation?
    Am J Epidemiol, 165(8): 966-72. [Abstract] [Full-text]

© 2004-2010 Prostate Cancer Research Today. All Rights Reserved.